|  | Faller, Bernard / Urban, Laszlo (eds.) Hit and Lead Profiling Identification and Optimization of Drug-like Molecules Methods and Principles in Medicinal Chemistry (Volume 43) Edited by Mannhold, Raimund / Kubinyi, Hugo / Folkers, Gerd
  1. Edition - August 2009 175.- Euro 2009. XXX, 503 Pages, Hardcover 82 Fig. (16 Colored Fig.), 35 Tab. - Handbook/Reference Book - ISBN-10: 3-527-32331-7 ISBN-13: 978-3-527-32331-9 - Wiley-VCH, Weinheim

Content
Sample Chapter
Index
Short description By addressing both drug efficiency and drug safety, this modern practical reference shows how each aspect shapes the key decisions for assessing the risk/benefit ratio of any novel compound during the early drug development stages, using both in vitro and in silico methods.
From the contents PART 1: Introduction: The one Airplane that Flies - Selection of the Right one Molecule for Clinical use. 1 Process logistics, testing strategies and automation aspects 2 Prediction of drug-likeness and its integration 3 Integrative risk assessment PART 2: ADME Profiling: What is Drug Likeness? 4 Solubility and Aggregation 5 In silico tools and in vitro HTS approaches to determine lipophilicity during the drug discovery process 6 Membrane permeability - measurement and prediction in drug discovery 7 Drug Metabolism and Reactive Metabolites 8 Drug-Drug Interactions: Screening for liability and assessment of risk 9 Plasma Protein Binding and Volume of Distribution: Determination, Prediction and Use in Early Drug Discovery 10 Putting it all together PART 3: Safety Profiling: What is Considered Safe in the Clinic? 11 Genetic Toxicity: in vitro Approaches for Hit and Lead Profiling 12 In vitro Safety Pharmacology Profiling: An important tool to decrease attrition 13 Knowledge-based and Computational Approaches to in vitro Safety Pharmacology PART 4: Organ Specific Toxicity 14 Discovery Toxicology Screening: Predictive, In Vitro Cytotoxicity 15 Predicting Drug-Induced Hepatotoxicity: In Vitro, In Silico, and In Vivo Approaches 16 Should cardiosafety be ruled by hERG inhibition? Early testing scenarios and integrated risk assessment 17 Haematotoxicity: in vitro and ex vivo compound profiling 18 Profiling Adverse Immune Effects 19 In Vitro Phototoxicity Testing: A Procedure Involving Multiple Endpoints
|
|
|
|